Analyst Price Targets — AMLX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:16 pm | — | Mizuho Securities | $19.00 | $14.10 | TheFly | Amylyx price target raised to $19 from $18 at Mizuho |
| February 10, 2026 11:10 am | Andrew Fein | H.C. Wainwright | $28.00 | $14.22 | TheFly | Amylyx price target raised to $28 from $20 at H.C. Wainwright |
| October 29, 2025 12:46 pm | — | Mizuho Securities | $16.00 | $13.94 | TheFly | Amylyx price target raised to $16 from $12 at Mizuho |
| October 16, 2025 11:13 am | Joel Beatty | Robert W. Baird | $19.00 | $15.79 | TheFly | Amylyx price target raised to $19 from $10 at Baird |
| September 15, 2025 10:38 am | Seamus Fernandez | Guggenheim | $25.00 | $11.85 | TheFly | Amylyx price target raised to $25 from $17 at Guggenheim |
| June 24, 2025 10:13 am | Seamus Fernandez | Guggenheim | $17.00 | $6.41 | TheFly | Amylyx initiated with a Buy at Guggenheim |
| May 6, 2025 9:00 pm | Marc Goodman | Leerink Partners | $10.00 | $4.65 | TheFly | Leerink upgrades Amylyx on avexitide growth opportunity |
| November 18, 2024 8:31 am | Joel Beatty | Robert W. Baird | $11.00 | $4.76 | StreetInsider | Baird Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Outperform |
| October 23, 2024 6:03 am | Geoff Meacham | Bank of America Securities | $10.00 | $4.53 | StreetInsider | BofA Securities Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Buy |
| October 18, 2024 6:44 am | Andrew Fein | H.C. Wainwright | $8.00 | $3.92 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX) |
Latest News for AMLX
Amylyx Pharmaceuticals (NASDAQ: AMLX) is entering what it described as a pivotal year for its lead program, avexitide, with Phase 3 data expected in the third quarter and preparations underway for a potential commercial launch in 2027, Chief Financial Officer Jim Frates said during a Needham investor session hosted by biotech analyst Ami Fadia. Frates said
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia.
Ally Bridge Group NY LLC acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 437,391 shares of the company's stock, valued at approximately $5,944,000. Amylyx Pharmaceuticals makes up approximately 3.6%
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMLX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.